Back to Report Store Home

Global Biosimilars Market – Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics

  • Published: Jan-2019
  • Report Code: GBI096CBR
  • Report Format: pdf

Description

Table of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION

2.1 Defining Biosimilars

2.2 Comparative Analysis: Biosimilars vs Generics

2.3 Biobetters

2.4 Why Biosimilars? SWOT Analysis

3. KEY DRIVERS

3.1 Constrained Payer Environment

3.2 Cost-effectiveness

3.3 Patent expiration

4. KEY BARRIERS

4.1 Development complexities and cost

4.2 Strategies from originators

4.3 Interchangeability and substitution concerns

5. BIOSIMILARS IN MATURE MARKETS

5.1 Biosimilar Approval Pathways Across Key Mature Markets

5.2 Biosimilars in EU

5.2.1 Developments in the EU Biosimilar Landscape: Gainsharing

5.3 Biosimilars in the US

5.3.1 Developments in the US Biosimilar Landscape: Reimbursement

5.3.2 Developments in the US Biosimilar Landscape: Rebate

5.4 Biosimilars in Japan

6. BIOSIMILARS IN EMERGING MARKET

6.1 Biosimilar Approval Pathways Across Key Emerging Markets

6.2 Biosimilars in South Korea

6.3 Biosimilars in China

6.3.1 Developments in the Chinese Biosimilar Landscape:

Reforms

6.3.2 Developments in the Chinese Biosimilar Landscape:

Investments

6.4 Biosimilars in Brazil

6.5 Biosimilars in India

6.6 Strategies for Biosimilars Manufacturers in Emerging Markets

7. GLOBAL BIOSIMILAR PIPELINE ANALYSIS

7.1 Global Biosimilar Pipeline by Stage of Development

7.2 Global Biosimilar Pipeline by Therapy Area

7.3 Global Biosimilar Pipeline by Indication: Top 10 targeted

indications

7.4 Global Biosimilar Pipeline by Molecule: Top 10 targeted

biosimilars

7.5 Most Active Manufacturers in the Global Biosimilar Pipeline:

Product Volume by Stage of Development

7.6 Most Active Manufacturers in the Global Biosimilar Pipeline:

Product Volume by Molecule

7.7 Most Active Manufacturers in the Global Biosimilar Late Stage

Pipeline

8. GLOBAL BIOSIMILAR MARKET AND PRODUCT SALES FORECAST

8.1 Global Rituximab Biosimilar Market Forecast 2017 – 2024

8.2 Rituximab Biosimilar Market: ABP 798 Global Sales Forecast 2017 – 2024

8.3 Global Infliximab Biosimilar Market Forecast 2017 – 2024

8.4 Infliximab Biosimilar Market: Inflectra Global Sales Forecast 2017 – 2024

8.5 Global Trastuzumab Biosimilar Market Forecast 2017 – 2024

8.6 Trastuzumab Biosimilar Market: Kanjinti Global Sales Forecast 2017 – 2024

8.7 Global Bevacizumab Biosimilar Market Forecast 2017 – 2024

8.8 Bevacizumab Biosimilar Market: Mvasi Global Sales Forecast 2017 – 2024

8.9 Global Adalimumab Biosimilar Market Forecast 2017 – 2024

8.10 Adalimumab Biosimilar Market: Global Imraldi Sales Forecast 2017 – 2024

8.11 Insulin Glargine Biosimilar Market: Basaglar Global Sales Forecast 2017 – 2024

8.12 Etanercept Biosimilar Market: Benepali Global Sales Forecast 2017 – 2024

9. STRATEGIC ALLIANCES

9.1 Global Biosimilar Partnership Deals by Region and Value

9.2 Global Biosimilars Partnership Deals by Year

9.3 Global Biosimilar Licensing Deals by Region and Value

9.4 Global Biosimilar Licensing Deals by Year

9.5 Top 10 Targeted Biosimilars in Strategic Alliances

9.6 Most Active Companies in Strategic Alliances

10. COMPANY PROFILE

10.1 Sandoz

10.2 Pfizer

10.3 Celltrion

10.4 Samsung Bioepis

10.5 Amgen

10.6 Biocon

10.7 Dr. Reddy's Laboratories

11. BIBLIOGRAPHY

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$2995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$5990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$8985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards